HC Wainwright Rates Conexeu Sciences (CNXU) buy, $20 Price Target
HC Wainwright maintains a buy rating for Conexeu Sciences, setting a $20 price target, a 87.09% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
HC Wainwright rated Conexeu Sciences Inc. ($CNXU) "buy" with a $20 price target on June 22, 2026.
Since the rating, $CNXU is down 15.9% after 1 week, down 23.3% after 1 month and down 74.9% to date (from the $12.18 close on Jun 22, 2026).
CNXU
Conexeu Sciences Inc.
Key Points
- HC Wainwright reiterated its buy rating on Conexeu Sciences (CNXU) with a $20 price target on June 22, 2026.
- HC Wainwright's $20 price target implies 87.09% upside from Conexeu Sciences Inc.'s ($CNXU) current $10.69 share price.
- Shares of CNXU traded at $13.28 on Tuesday, with a market cap of about $325.9 million and a 52-week range of $9.60 to $18.79.
- Conexeu Sciences, a biotech firm focused on regenerative tissue products, remains a focus of analyst attention with a reiterated buy rating.
Get $CNXU trade alerts by text
We text you when insiders, Congress or big funds trade $CNXU. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Conexeu Sciences Inc. alert may contain errors. Disclosures
HC Wainwright has reiterated its buy rating on Conexeu Sciences Inc. (NasdaqCM:CNXU), maintaining a price target of $20. The rating and target were confirmed on June 22, 2026, by analyst Swayampakula Ramakanth.
HC Wainwright & Co. vs. the S&P 500
Hypothetical returns from HC Wainwright & Co.'s disclosed trades, not real profit or advice. How we model this.
Conexeu Sciences Inc. Stock Up 115.5%
Shares of NasdaqCM:CNXU traded near $13.28 on Tuesday. Conexeu Sciences Inc. has a market cap of approximately $325.9 million. The stock has seen a 52-week low of $9.60 and a high of $18.79. It has a 50-day moving average of $13.58, matching its 200-day moving average. The company's financial health is highlighted by a strong current ratio of 8.512 and a quick ratio of 7.139, with a low debt-to-equity ratio of 0.055.
$CNXU price target
Conexeu Sciences Inc. daily closes and this analyst's $20 target. Not advice.
About Conexeu Sciences
Conexeu Sciences Inc., based in Reno, Nevada, operates in the healthcare sector, specifically within biotechnology. The company develops collagen-based regenerative tissue scaffold products used in medical aesthetics and tissue repair. Its offerings include a patented collagen extracellular matrix scaffold platform for various applications like wound care and facial rejuvenation. Founded in 2022, Conexeu is led by CEO Mr. Miles D. Harrison and focuses on innovative solutions for the beauty, aesthetics, and medical sectors.
Bottom Line
HC Wainwright's reiteration of a buy rating with a $20 target underscores continued interest in Conexeu Sciences. The biotech firm, known for its regenerative tissue products, remains a notable player in the healthcare sector. Investors keep an eye on such analyst ratings as part of their broader strategy, though it's important to note that these are backward-looking assessments.
Related Filing Alerts
Source: HC Wainwright's rating change on $CNXU (Jun 22, 2026). Written by software, not financial advice. How we make alerts